NCT03926624 2026-01-22
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Delta-Fly Pharma, Inc.
Phase 3 Terminated
Clinical Trials
24 trialsNCT07348575 2026-01-16
A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
Second Affiliated Hospital of Nanchang University
Phase 3 Enrolling by invitation
NCT04229979 2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3 Active not recruiting
NCT05586074 2025-04-09
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Sunshine Lake Pharma Co., Ltd.
Phase 3 Recruiting
NCT02085408 2024-12-13
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT03306264 2024-08-27
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT00043381 2024-08-02
Decitabine Versus Supportive Care in Adults With Advanced-stage MDS
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT06297772 2024-06-04
Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR
Ruijin Hospital
Phase 3 Not yet recruiting
NCT06073730 2023-10-10
Viale-a
The Second Affiliated Hospital of Kunming Medical University
Phase 3 Unknown
NCT05351346 2023-03-24
Genotype-guided Treatment in DLBCL
Ruijin Hospital
Phase 3 Recruiting
NCT03941964 2023-03-20
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
AbbVie
Phase 3 Completed
NCT02172872 2023-02-15
"InDACtion" vs "3+7" Induction in AML
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Unknown
NCT01303796 2022-06-22
SEAMLESS
Cyclacel Pharmaceuticals, Inc.
Phase 3 Completed
NCT05382390 2022-05-19
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial
Shengjing Hospital
Phase 3 Unknown
NCT03257241 2021-10-01
PALG-AML1/2016
Polish Adult Leukemia Group
Phase 3 Unknown
NCT04292769 2020-03-03
Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors
Chinese PLA General Hospital
Phase 3 Unknown
NCT04087967 2019-09-12
Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT00260832 2019-09-11
Trial of Decitabine in Patients With Acute Myeloid Leukemia
Eisai Inc.
Phase 3 Completed
NCT04083911 2019-09-10
Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT02785900 2018-12-12
CASCADE
Seagen Inc.
Phase 3 Terminated
NCT03553537 2018-06-12
Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Southwest Hospital, China
Phase 3 Unknown
NCT02985372 2016-12-07
Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia
Shandong University
Phase 3 Unknown
NCT01633099 2012-07-06
Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients
ChineseAMS
Phase 3 Unknown
NCT00043134 2010-04-13
Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 3 Unknown